Cellectar to Release Top-line Data from WM Pivotal Trial During the JP Morgan Healthcare Conference the Week of January 8, 2024 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
The European Medicines Agency has granted Priority Medicines designation to iopofosine I-131 for use in patients with Waldenström macroglobulinemia in patients who previously received at least 2 treatment regimens.
Nirsevimab significantly protected infants against RSV disease in Phase III MELODY trial astrazeneca.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from astrazeneca.com Daily Mail and Mail on Sunday newspapers.
Nirsevimab significantly protected infants against RSV disease in Phase 3 trial Nirsevimab showed a 74.5% reduction in lower respiratory tract infections caused by RSV requiring medical care in healthy
Nirsevimab EMA regulatory submission accepted under accelerated assessment for RSV protection in all infants miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.